Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

INTRODUCTION: Although the human epidermal growth factor receptor 2 (HER2) blocker trastuzumab is generally well tolerated, cardiotoxicity can be an important therapeutic limitation. OBJECTIVE: In this prespecified analysis, we compared the cardiac safety of the trastuzumab biosimilar ABP 980 (KANJI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolberg, Hans-Christian, Colleoni, Marco, Demetriou, Georgia Savva, Santi, Patricia, Tesch, Hans, Fujiwara, Yasuhiro, Tomasevic, Zorica, Hanes, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048858/
https://www.ncbi.nlm.nih.gov/pubmed/31927716
http://dx.doi.org/10.1007/s40264-019-00886-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048858/
https://www.ncbi.nlm.nih.gov/pubmed/31927716
http://dx.doi.org/10.1007/s40264-019-00886-3

Ejemplares similares